

Strength to Monitoring the Natural Anticoagulants Protein C and Antithrombin III

George Zhu*

University Hospital Leiden, The Netherlands

***Corresponding Author:** George Zhu, University Hospital Leiden, The Netherlands.

Received: October 19, 2022; **Published:** November 17, 2022

During the past decades a number of new anticoagulative proteins have been identified that play an important role in the regulation of hemostatic balance [1]. These proteins included antithrombin III (ATIII), protein C and its inhibitor, protein S and thrombomodulin. In except for ATIII, the others form the components of the protein C pathway.

The cDNA codes for human protein C protein which consists of a preproleader sequence of 42 amino acids, a light chain region of 155 amino acids, a connecting dipeptide of lys-Arg and a heavy chain region of 262 amino acids [2,3]. During intracellular processing, the preproleader sequence removed, protein C is secreted as a mature protein of 419 amino acids.

Protein C (PC), a vitamin K-dependent plasma protein, and its inhibitor of activated protein C (APCI) are part of a major regulatory system of hemostasis. Activated protein C destroys the activity of activated factor V and VIII. Protein S as cofactor of activated protein C (APC) is due to the inability of APC to prolong the APTT or the Va-induced clotting time in protein S deficient plasma [4]. APC and protein S complex could inactivate factor Va and VIIIa more rapidly under the condition of calcium and phospholipids than did APC alone [5,6]. More recent, it has been found that protein S drives cancer cell proliferation and cell survival via oncogenic receptor Axl [7-12]. Aberrant activation of RTKs often leads to malignant transformation, whereas PI3K/Axl is required for this oncogenic receptor signaling [13]. Targeting against a deregulated dominant oncogenic receptor such as the oncogenic estrogen receptor (ER) pathway (tamoxifen) [14-28] and blocking oncogenic receptor HER3/HER2 agent trastuzumab is enough to slow tumor progression [25-32].

At present, the oncogenic receptors and their target antibodies (Abs) [33] strategies have been widely extended to CD44 oncogenic receptor of hyaluronic acid (HA) [34], RAGE oncogenic receptor [35-38], the oncogenic receptor platelet-derived growth factor receptor- β (PDGFR β) or PDGFR α linked to the pathogenesis of myeloproliferative neoplasm or chronic leukemia [26,39,40], cytokine IL-3/oncogenic receptor IL3R, oncogenic IL7R [41], IL-11/IL-11 gp130 receptor pro-oncogenic signaling [24,42-44] and oncogenic receptor IL17rb [45,46]. Intriguing, in Wilmes' article [47,48], homodimeric class I cytokine receptors TpoR, EpoR and GHR are normally dimerized by their ligands. These receptors lack intrinsic kinase activity, relying on the associated the pseudokinase domain (PK) of Janus kinase 2 (JAK2) proteins to initiate signal transduction. Notably, oncogenic receptors (TpoR W515L, oncogenic EpoR and GHR) and hyperactive JAK2 mutants (TpoR TM-JM and JAK2 PK domain) promoted stronger and stable ligand-dimerization as prerequisite for signal activation. Ligand-independent dimerization was in further enhanced upon coexpression of TpoR W515L and JAK2 V617F, which exerts their additive signaling activities. In the presence of JAK2 V617F ligand- independent dimerization reached to -50% of the maximum level for TpoR, -25% for EpoR, and -10% for GHR, respectively.

In clinics, decreased plasma PC levels can predispose an individual to thrombotic disease, whereas decreased levels of APCI can cause hemorrhages. Patients with recurrent thrombo- embolic episodes of unknown etiology would be monitoring for the assessment of protein

C deficiency. Congenital protein C deficiencies were reported at earliest by Griffin JH in 1981 [49] and by Bertina RM in 1982 [50,51]. Hereditary protein S deficiency was identified in three Dutch families by Broekmans AW in 1985 [52]. At present, protein C antigen was determined by electroimmunoassay as described elsewhere.

The term “antithrombin” was first postulated by Morawitz in 1905 [53]. Antithrombin III (ATIII) is an α_2 - globulin with ellipsoid form. The single polypeptide chain contains 425 amino acids. Heparin belongs to the glycosaminoglycans (GAGs), which are sulphated carbohydrates widely distributed in human [54]. The binding of heparin to ATIII induce conformational changes which facilitate the binding of thrombin. Upon the formation of a stable thrombin-ATIII complex, heparin is released and joins another AT molecule [55-58]. The data suggested that lysine was required for heparin binding. Another intact serine at the active site of thrombin was also essential for reaction with ATIII [55]. Thrombin and ATIII form an inactive complex in a 1:1 molar ratio. ATIII also inactivates factor IXa, Xa, XIa and XIIa at slow rates [55,56]. In clinical aspects, regarding the assay method for routine work, the clotting assays for determining ATIII activity (ATIII:C) is to be complicated. ATIII antigen (ATIII:Ag) was measured using immunoassays (EIA). The method is simple, cheap and require about 20 hours, but cannot detect all congenital ATIII deficiencies. Egeberg O and Abildgaard U (1965, 1970) [59,60] reported the results that mean ATIII activity (ATIII:C) were about half the normal in the classical ATIII deficiency and the affected family members.

In cirrhosis of the liver, the protein C antigen and the ATIII concentration are often low and was positively correlation with serum albumin levels [12,61-64]. In biliary tract occlusion and primary biliary cirrhosis, normal PC and ATIII concentrations were found. These data indicated that two natural anticoagulants (PC and ATIII) deficiencies occur the dysregulation of hepatic PC and ATIII synthesis and might play a central role as a predictor index in liver diseases.

In recent many topics were focused on coagulation and malignancy. Some haemorrhagic and thromboembolic complications are frequent in patients with malignancy. Acute leukemias varied in PC and ATIII level [12,61,62,65]. The decreased PC concentration was frequently found in individuals with M5 subtype and hyper- leukocytic acute leukemias. Plasma PC:Ag and ATIII:Ag level had no significant lower in some patients with acute promyelocytic leukemia (APL) complicated by DIC, which suggested the coagulopathy in APL might be due to mechanisms different from other forms of DIC such as infectious disease (e.g. septic shock) [12,61,65]. Many authors [66] described that a procoagulant activity was in term of ‘cancer coagulative factor’, ‘cancer cell procoagulant activities’, ‘leukemic cell mediated procoagulant activities’ [65], ‘cancer procoagulant A (CPA)’ which was presented in malignant cells. The most prevalences are that low PC and ATIII levels were detected both in clinical infectious and experimental DIC, and the term ‘consumption coagulopathy’ characterized this PC and ATIII decrease [67]. Thus, the PC and ATIII assays are helpful to monitoring the disease progress and act as an important biomarker or predictable marker.

Bibliography

1. Stenflo J. “A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization”. *Journal of Biological Chemistry* 251 (1976): 355-363.
2. Foster DC., *et al.* “The nucleotide sequence of the gene for human protein C”. *Proceedings of the National Academy of Sciences of the United States of America* 82 (1985): 4673-4677.
3. Foster D and Davie EW. “Characterization of a cDNA coding for human protein C”. *Proceedings of the National Academy of Sciences* 81 (1984): 4766-4770.
4. Bertina RM., *et al.* “Determination of plasma protein S - the protein co-factor of activated protein C”. *Thrombosis and Haemostasis* 53 (1985): 268-272.
5. Suzuki K., *et al.* “Regulation of activated protein C by thrombin-modified protein S”. *Journal of Biochemistry* 94 (1983): 699-705.

6. Lawrence JE, *et al.* "Protein S enhances the inactivation of factor VIII by activated protein C". *Thrombosis and Haemostasis* 54 (1985): 83.
7. Abboud-Jarrous G, *et al.* "Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of Axl". *Oncotarget* 8.8 (2017): 13986-14002.
8. Lee N, *et al.* "2-Deoxy-D-glucose-induced metabolic alteration in human oral squamous SCC15 cells: involvement of N-glycosylation of Axl and Met". *Metabolites* 9 (2019): 188.
9. Song XZ, *et al.* "Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase Axl in pancreatic cancer". *Journal of Biological Chemistry* 295.8 (2020): 2348-2358.
10. Nuzzo S, *et al.* "Axl-targeted delivery of the oncosuppressor miR-137 in non-small-cell lung cancer". *Molecular Therapy: Nucleic Acids* 17 (2019): 256-263.
11. Wimmel A, *et al.* "Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 in human lung carcinoma cells". *Cancer* 86 (1999): 43-49.
12. Zhu G, *et al.* "Clinical application of plasma protein C determination". *Universal Journal of Pharmaceutical Research* 5.6 (2020): 29-35.
13. Utermark T, *et al.* "The p110 α and p110 β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis". *Genes and Development* 26 (2012): 1573-1586.
14. Green S and Chambon P. "Carcinogenesis: A superfamily of potentially oncogenic hormone receptors". *Nature* 324 (1986): 615-617.
15. Chin HMS, *et al.* "Need for multi-scale systems to identify spindle orientation regulators relevant to tissue disorganization in solid cancers". *Frontiers in Physiology* 5 (2014): 278.
16. Singh RR and Kumar R. "Steroid hormone receptor signalling in tumorigenesis". *Journal of Cellular Biochemistry* 96 (2005): 490-505.
17. Elangovan S, *et al.* "SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer". *Cancer Research* 71.21 (2011): 6654-6664.
18. Zinger L, *et al.* "Ligand-binding domain-activating mutations of ESR1 rewire cellular metabolism of breast cancer cells". *Clinical Cancer Research* 25.9 (2019): 2900-2914.
19. Ludwik KA, *et al.* "ER α -mediated nuclear sequestration of RSK2 is required for ER+ breast cancer tumorigenesis". *Cancer Research* 78.8 (2018): 2014-2025.
20. Veeraraghavan J, *et al.* "Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers". *Nature Communications* 5 (2014): 4577.
21. Tilli MT, *et al.* "Introduction of ER α into the tTA/Tag conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma". *The American Journal of Pathology* 163 (2003): 1713-1719.
22. Davis VL. "Expression of a dominant negative estrogen receptor alpha variant in transgenic mice accelerates uterine cancer induced by the potent estrogen diethylstilbestrol". *Reproductive Toxicology* 34 (2012): 512-521.
23. Yue W, *et al.* "Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis". *Steroids* 78 (2013): 161-170.

24. Zhu G. "Ep CAM, an old cancer antigen, turned oncogenic receptor and its targeting immunotherapy". *Universal Journal of Pharmaceutical Research* 3.2 (2018): 41-46.
25. Marx C., et al. "Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer". *Molecular Pharmacology* 71.6 (2007): 1525-1534.
26. Zhu G. "Targeting oncogenic receptor: From molecular physiology to currently the standard of target therapy". *Advance Pharmaceutical Journal* 2.1 (2017): 10-28.
27. Hickey TE., et al. "Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer". *British Journal of Cancer* 125.12 (2021): 1599-1601.
28. De Bacco F., et al. "Receptor tyrosine kinases as targets for cancer therapy". *Cancer Therapy* 2 (2004): 317-328.
29. Moody P., et al. "Receptor crosslinking: A general method to trigger internalization and lysosomal targeting of therapeutic receptor: ligand complexes". *Molecular Therapy* 23 (2015): 1888-1898.
30. Del Mar Maldonado M., et al. "Targeting Rac and Cdc42 GEFs in metastatic cancer". *Frontiers in Cell and Developmental Biology* 8 (2020): 201.
31. Duarte HO., et al. "Gastric cancer cell glycosylation as a modulator of the ErbB2 oncogenic receptor". *International Journal of Medical Sciences* 18 (2017): 2262.
32. Jenke R., et al. "SATB1-mediated upregulation of the oncogenic receptor tyrosine kinase HER3 antagonizes Met inhibition in gastric cancer cells". *International Journal of Molecular Sciences* 22 (2021): 82.
33. Yang XM., et al. "Targeting the Tumor Micro- environment with Interferon- β Bridges Innate and Adaptive Immune Responses". *Cancer Cell* 25 (2014): 37-48.
34. He H and Maruta H. "Oncogenicity of PAKs and their substrates. In Merlin-an overview". *Emery and Rimoin's Principles and Practice of Medical Genetics* (2013): 266-268.
35. Radia AM., et al. "Specific siRNA targeting receptor for advanced glycation and products (RAGE) decreases proliferation in human breast cancer cell lines". *International Journal of Molecular Sciences* 14.4 (2013): 7959-7978.
36. Xu XC., et al. "Knockdown of RAGE inhibits growth and invasion of gastric cancer cells". *European Journal of Histochemistry* 57 (2013): 636.
37. Wang D., et al. "Overexpression of the receptor for advanced glycation end products (RAGE) is associated with poor prognosis in gastric cancer". *PloS One* 10.4 (2015): e0122697.
38. Zhang Q., et al. "Receptor for advanced glycation end-products (RAGE) is over- expressed in human osteosarcoma and promotes the proliferation of osteosarcoma U-20S cells in vitro". *Genetics and Molecular Research* 15.2 (2016): gmr7817.
39. Esposito CL., et al. "Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives". *Genes* 9 (2018): 529.
40. Zhu G. "Use of traditional medicine in severe edema amelioration of refractory congestive heart failure - case report". *Blood, Heart and Circulation* 2.1 (2018): 1-2.

41. Mansour MR, *et al.* "Targeting Oncogenic Interleukin-7 Receptor Signalling with Nacetylcysteine in T-cell acute lymphoblastic leukaemia". *British Journal of Haematology* 168.2 (2015): 230-238.
42. Ernst M and Putoczki T. "Molecular pathways: IL11 as a tumor-promoting cytokine-translational implications for cancers". *Clinical Cancer Research* 20.22 (2014): 5579-5588.
43. Merchant JL. "What lurks beneath: IL-11, via stat-3, promotes inflammation-associated gastric tumorigenesis". *Journal of Clinical Investigation* 118.5 (2008): 1628-1631.
44. Ernst M, *et al.* "STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice". *Journal of Clinical Investigation* 118 (2008): 1727-1738.
45. Huang SC, *et al.* "TGF-beta secreted by Tregs in lymph nodes promotes breast cancer malignancy via upregulation of IL-17RB". *EMBO Molecular Medicine* 9 (2017): 1660-1680.
46. Poultsidi A, *et al.* "Lymph node cellular dynamics in cancer and HIV: what can we learn for the follicular CD4(Tfh) cells?". *Frontiers in Immunology* 9 (2018): 2233.
47. Staerk J, *et al.* "Orientation-specific signalling by thrombopoietin Receptor dimers". *The EMBO Journal* 30 (2011): 4398-4413.
48. Wilmes S, *et al.* "Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations". *Science* 367.6478 (2020): 643-652.
49. Griffin JH, *et al.* "Deficiency of protein C in congenital thrombotic disease". *Journal of Clinical Investigation* 68 (1981): 1370-1373.
50. Bertina RM, *et al.* "Protein C deficiency in a Dutch family with thrombotic disease". *Thrombosis and Haemostasis* 48 (1982): 1-5.
51. Broekmans AW, *et al.* "Congenital protein C deficiency and venous thrombo- embolism. A study in three Dutch families". *The New England Journal of Medicine* 309 (1983): 340-344.
52. Broekmans AW, *et al.* "Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families". *Thrombosis and Haemostasis* 53 (1985): 273-277.
53. Morawitz P. "Die Chemie der Blutgerinnung". *Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie* 4 (1905): 307-422.
54. Danishefsky I, *et al.* "Human antithrombin III. Carbohydrate components and associated glycolipid". *The Journal of Biological Chemistry* 253 (1978): 32-37.
55. Abildgaard U. "Binding of thrombin to antithrombin III". *Scandinavian Journal of Clinical and Laboratory Investigation* 24 (1969b): 23-27.
56. Rosenberg RD and Damus PS. "The purification and mechanism of action of human antithrombin- heparin cofactor". *The Journal of Biological Chemistry* 248 (1973): 6490-6505.
57. Li EHH, *et al.* "The role of heparin in the thrombin- antithrombin III reaction". *Archives of Biochemistry and Biophysics* 175 (1976): 153-159.
58. Machovich R, *et al.* "Action of heparin on thrombin-antithrombin reaction". *Biochemica et Biophysica Acta* 379 (1975): 193-200.
59. Egeberg O. "Inherited antithrombin deficiency causing thrombophilia". *Thrombosis et Diathesis Haemorrhagica* 13 (1965): 516-530.

60. Abildgaard U., *et al.* "Assay of progressive antithrombin in plasma". *Thrombosis et Diathesis Haemorrhagica* 24 (1970b): 224-229.
61. Griffin JH., *et al.* "Protein C, an antithrombotic protein is reduced in hospitalized patients deficiencies of protein C, an inhibitor of blood coagulation". *Blood* 60.1 (1982): 261-264.
62. Mannucci PM., *et al.* "Deficiencies of protein C, an inhibitor of blood coagulation". *Lancet* 2 (1982): 463-467.
63. Mannucci L., *et al.* "Value of Normotest and antithrombin III in the assessment of liver function". *Scandinavian Journal of Gastroenterology and Supplement* 19 (1973): 103-107.
64. Nagy I., *et al.* "Heparin induced change of antithrombin III(AT III) activity in chronic active hepatitis and liver cirrhosis". Proceedings, Symposium and Round Table Conferences of the 10th International Congress of Gastroenterology, Budapest (1976).
65. Zhu G and Li JX. "Plasma concentration of the natural anti-coagulants protein C and antithrombin III in leukemia". *Thrombosis and Haemostasis* 62 (1989): 391.
66. Donati MB., *et al.* "Coagulation and malignancy". In Poller L (edition) Recent advances in blood coagulation (1981): 227-259.
67. Fourrier F., *et al.* "Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies". *Chest* 101.3 (1992): 816-823.

Volume 5 Issue 12 December 2022

© All rights reserved by George Zhu.